Abstract
Non-small cell lung cancer (NSCLC) accounts for more deaths than any other cancer. Treatments are limited, and prognoses are usually very poor. Amitripyline is a tricyclic antidepressant with multiple effects which may give a variety of benefits to lung cancer patients. Effects on pain, mood, and sleep are of clear potential benefit and are well established, whereas effects on cough and respiratory function are currently under investigation. In addition, potential antitumour effects have yet to be comprehensively tested. Beneficial effects are limited by dose dependent toxicity and adverse effects. Nevertheless, amitriptyline appears to have place in the management of lung cancer and warrants further investigation.
Keywords: Amitriptyline, lung cancer, non-small cell lung cancer, NSCLC.
Current Cancer Therapy Reviews
Title:The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Volume: 10 Issue: 3
Author(s): John C. Ashton
Affiliation:
Keywords: Amitriptyline, lung cancer, non-small cell lung cancer, NSCLC.
Abstract: Non-small cell lung cancer (NSCLC) accounts for more deaths than any other cancer. Treatments are limited, and prognoses are usually very poor. Amitripyline is a tricyclic antidepressant with multiple effects which may give a variety of benefits to lung cancer patients. Effects on pain, mood, and sleep are of clear potential benefit and are well established, whereas effects on cough and respiratory function are currently under investigation. In addition, potential antitumour effects have yet to be comprehensively tested. Beneficial effects are limited by dose dependent toxicity and adverse effects. Nevertheless, amitriptyline appears to have place in the management of lung cancer and warrants further investigation.
Export Options
About this article
Cite this article as:
C. Ashton John, The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/157339471003150212112220
DOI https://dx.doi.org/10.2174/157339471003150212112220 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assembly of Quinoline, Triazole and Oxime Ether in a Single Molecular Entity: A Greener and One-pot Synthesis of Novel Oximes as Potential Cytotoxic Agents
Letters in Drug Design & Discovery Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?
Current Molecular Pharmacology Possible Binding Mode Analysis of Pyrazolo-triazole Hybrids as Potential Anticancer Agents through Validated Molecular Docking and 3D-QSAR Modeling Approaches
Letters in Drug Design & Discovery c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy
Current Medicinal Chemistry An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Deciphering the Systems Biology of mTOR Inhibition by Integrative Transcriptome Analysis
Current Pharmaceutical Design Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
Current Topics in Medicinal Chemistry MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma
Current Pharmaceutical Design Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts
Current Cancer Drug Targets In vivo Cancer Imaging with Semiconductor Quantum Dots
Current Pharmaceutical Analysis The Role of Stress Proteins in Prostate Cancer
Current Genomics Biomarkers Obtained by Non-Invasive Methods in Patients with COPD: Where do we Stand, what do we Expect?
Current Medicinal Chemistry Editorial [Hot topic: Apoptosis in Carcinogenesis and Cancer Therapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Cancer Drug Targets Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry